Profiles

Keywords
Last Name
Institution

Connection

Parameswaran Venugopal to Combined Modality Therapy

This is a "connection" page, showing publications Parameswaran Venugopal has written about Combined Modality Therapy.

 
Connection Strength
 
 
 
0.262
 
  1. Karmali R, Nabhan C, Petrich AM, Raizer J, Peace D, Lukas R, Gordon LI, Basu S, Chukkapalli V, Venugopal P. Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma. Br J Haematol. 2017 Apr; 177(1):72-79.
    View in: PubMed
    Score: 0.141
  2. Rao R, Vugman G, Leslie WT, Loew J, Venugopal P. Lymphomatoid granulomatosis treated with rituximab and chemotherapy. Clin Adv Hematol Oncol. 2003 Nov; 1(11):658-60; discussion 660.
    View in: PubMed
    Score: 0.056
  3. Gilmore BA, Rodby RA, Cimbaluk D, Venugopal P, Patel P, Barton K, Hagen P, Rodriguez T, Sumoza L, Bishop MR, Dhakal B, Hari P, Paner A. When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):e251-e258.
    View in: PubMed
    Score: 0.041
  4. Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):467-74.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.